Articles related to MYELOMA

High-risk iFISH markers, such as CKS1B, IGH-FGFR3, and del17p, significantly affect survival outcomes in newly diagnosed multiple myeloma patients, with marked differences observed between high-risk and standard-risk cohorts.

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.

The addition of subcutaneous daratumumab to a standard myeloma regimen has been shown to significantly improve progression-free survival and response rates in transplantation-eligible patients with newly diagnosed multiple myeloma, according to a recent phase 3 clinical trial.

The study’s findings suggest that palliative radiotherapy could be a viable option for managing pain in multiple myeloma patients. With a complete response rate of 48% and a partial response rate of 38%, this treatment approach shows promise.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.